Overview

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Status:
RECRUITING
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
Phase:
PHASE1
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Treatments:
Bevacizumab